Yunnan Biovalley Pharmaceutical Co (BJSE:920266) ROC %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920266 Yunnan Biovalley Pharmaceutical Co Ltd BJSE:920266
74 GF Score
Price ¥7.57
GF Value ¥7.81
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Yunnan Biovalley Pharmaceutical Co ROC %?

Yunnan Biovalley Pharmaceutical Co BJSE:920266 74 ROC % is 0.00% as of Jun. 2026. GuruFocus rates BJSE:920266 with a GF Score™ of 74/100 and a GF Value™ of ¥7.81 (Fairly Valued). The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Yunnan Biovalley Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2026 was 0.00%.

As of today (2026-08-24), Yunnan Biovalley Pharmaceutical Co's WACC % is 8.59%. Yunnan Biovalley Pharmaceutical Co's ROC % is -1.42% (calculated using TTM income statement data). Yunnan Biovalley Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Yunnan Biovalley Pharmaceutical Co  (BJSE:920266) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Yunnan Biovalley Pharmaceutical Co's WACC % is 8.59%. Yunnan Biovalley Pharmaceutical Co's ROC % is -1.42% (calculated using TTM income statement data). Yunnan Biovalley Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Yunnan Biovalley Pharmaceutical Co ROC % Related Terms


Yunnan Biovalley Pharmaceutical Co ROC % Historical Data

* Premium members only.

The historical data trend for Yunnan Biovalley Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yunnan Biovalley Pharmaceutical Co ROC % Chart

Yunnan Biovalley Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.90 3.36 3.51 -1.46 -4.11

Yunnan Biovalley Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.33 -2.54 -1.73 -1.77 0.00
BJSE:920266
74GF Score
Yunnan Biovalley Pharmaceutical Co Ltd BJSE:920266
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yunnan Biovalley Pharmaceutical Co ROC % Calculation

Yunnan Biovalley Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-35.997 * ( 1 - 0% )/( (862.452 + 889.011)/ 2 )
=-35.997/875.7315
=-4.11 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1145.047 - 88.361 - ( 194.234 - max(0, 123.78 - 546.033+194.234))
=862.452

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1061.225 - 82.325 - ( 89.889 - max(0, 107.686 - 465.949+89.889))
=889.011

Yunnan Biovalley Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=3.752 * ( 1 - 100% )/( (844.644 + 878.431)/ 2 )
=0/861.5375
=0.00 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1052.094 - 73.365 - ( 134.085 - max(0, 98.822 - 457.987+134.085))
=844.644

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1019.811 - 58.786 - ( 82.594 - max(0, 68.816 - 431.021+82.594))
=878.431

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 0.00% mean?
Yunnan Biovalley Pharmaceutical Co (BJSE:920266) has a ROC % of 0.00% as of Jun. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors.
Is Yunnan Biovalley Pharmaceutical Co's ROC % too high?
Yunnan Biovalley Pharmaceutical Co's current ROC % is 0.00%. Overall, Yunnan Biovalley Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Yunnan Biovalley Pharmaceutical Co's ROC % compare to ZTS?
Yunnan Biovalley Pharmaceutical Co's ROC % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.60, based on 993 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yunnan Biovalley Pharmaceutical Co's current ROC % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yunnan Biovalley Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co (BJSE:920266) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.81, compared to a current price of ¥7.57 — trading 3.1% below its estimated fair value. The current ROC % is 0.00%. Yunnan Biovalley Pharmaceutical Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Yunnan Biovalley Pharmaceutical Co (BJSE:920266), the current ROC % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yunnan Biovalley Pharmaceutical Co (BJSE:920266) Overvalued in 2026?

Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.57 is trading 3.1% below its estimated GF Value™ of ¥7.81. GuruFocus considers Yunnan Biovalley Pharmaceutical Co to be Fairly Valued.

Key valuation signals for BJSE:920266:

  • ROC %: 0.00%
  • GF Value™: ¥7.81 vs. price of ¥7.57 (3.1% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the BJSE:920266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Yunnan Biovalley Pharmaceutical Co Business Description

Address No. 999 Biological Valley Street, Majinpu New District, High-tech Zone, Yunnan Province, Kunming City, CHN, 650500
Yunnan Biovalley Pharmaceutical Co Ltd engages in research and development, production, and marketing of pharmaceuticals and health care based on herbal medicines. The products on the market include breviscapine injection, breviscapine Shengmai capsules, breviscapine tablets, breviscapine dripping pills, Erigeron Capsules, Erigeron Soft Capsules.
74GF Score

Get the complete analysis for BJSE:920266

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.57
Price
¥7.81
GF Value